Percheron Therapeutics Ltd (ASX:PER, OTC:PERCF) last week outlined progress on its lead oncology asset HMBD-002, positioning the immunotherapy program to move into Phase II clinical testing following ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results